Dexcom G4 CGM Approved for use in Children as Young as Two Years Old

Now Children Can Gain Better Control of Their Diabetes with Advanced CGM Technology

SAN DIEGO--(BUSINESS WIRE)-- Dexcom, Inc. (DXCM), (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today that it has received U.S. Food and Drug Administration (FDA) approval for its CGM device: Dexcom G4® PLATINUM (Pediatric) for use in children ages 2 to 17 years with diabetes. Already approved for adults 18 and older, the Dexcom G4 PLATINUM (Pediatric) is now the only CGM system approved for children as young as two years old.

Continuous glucose monitoring is considered the most significant breakthrough in diabetes management in the past 40 years.1 The traditional standard-of-care for blood glucose measurement has been a blood glucose meter. CGM is important because it can help educate kids on how to best learn to manage their diabetes into adulthood.

We are thrilled with the FDAs approval of our Dexcom G4 PLATINUM System in the pediatric population, said Terrance H. Gregg, CEO of Dexcom. Daily management is relentless, and parents can now have greater peace of mind that a childs diabetes is under control, whether the child is at home, away at school, or participating in activities or sports. The Dexcom G4 PLATINUM provides dynamic glucose information harnessing todays most innovative technology, so that persons with diabetes can go about their daily lives without added worry.

To read the entire article, please click here